Actually, IL-17 is overexpressed in a subset of lung cancer patients, it has been considered as an important cytokine in cancer promotion, and was reported to inhibit antitumor immune responses (71); plus, IL17 inflammatory phenotype could be caused by lower airway dysbiosis (67). The gene discussed is IL17A; the disease is lung carcinoma.